Literature DB >> 8451000

Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study.

D J Burn1, D J Brooks.   

Abstract

We studied 13 patients with severe drug-induced parkinsonism (DIP) using L-6-[18F]fluorodopa positron emission tomography (18F-dopa PET) to investigate the integrity of their dopaminergic nigrostriatal projections. Twelve of these patients were subsequently followed clinically for a median of 23.5 months (range, 6 to 49). Nine patients had normal putamen 18F-dopa uptake. In eight of these nine patients where follow-up was available, a normal 18F-dopa PET study was predictive of subsequent improvement of parkinsonism. Four of 13 DIP patients (31%) had significantly reduced putamen 18F-dopa uptake, within the Parkinson's disease range, and in three of these four (75%), this reduction was associated with continued, or worsening, parkinsonism. There were no clinical features at the time of PET that distinguished those who recovered and those who did not. We conclude that a normal 18F-dopa PET study correlates well with improvement from DIP, but an abnormal study does not necessarily indicate a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8451000     DOI: 10.1212/wnl.43.3_part_1.552

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

1.  Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients.

Authors:  Lior Greenbaum; Robert C Smith; Mordechai Lorberboym; Anna Alkelai; Polina Zozulinsky; Tzuri Lifschytz; Tzuri Lifshytz; Yoav Kohn; Ruth Djaldetti; Bernard Lerer
Journal:  Psychopharmacology (Berl)       Date:  2011-09-24       Impact factor: 4.530

2.  Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.

Authors:  Jose J Mateos; Francisco Lomeña; Eduard Parellada; Font Mireia; Emili Fernandez-Egea; Javier Pavia; Alberto Prats; Francisca Pons; Miquel Bernardo
Journal:  Psychopharmacology (Berl)       Date:  2006-09-22       Impact factor: 4.530

3.  Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism.

Authors:  Jose J Mateos; Francisco Lomeña; Eduardo Parellada; Mireia Font; Emili Fernandez; Javier Pavia; Alberto Prats; Francisca Pons; Miquel Bernardo
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

Review 4.  Imaging the head: functional imaging.

Authors:  G V Sawle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

5.  Positron emission tomography neuroimaging in Parkinson's disease.

Authors:  Clare Loane; Marios Politis
Journal:  Am J Transl Res       Date:  2011-07-10       Impact factor: 4.060

6.  Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism.

Authors:  P H Lee; J S Kim; D H Shin; S-N Yoon; K Huh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08-15       Impact factor: 10.154

7.  How useful is [123I]beta-CIT SPECT in clinical practice?

Authors:  J Eerola; P J Tienari; S Kaakkola; P Nikkinen; J Launes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

8.  Microstructural white matter alterations in patients with drug induced parkinsonism.

Authors:  Yoonju Lee; Yong Ho Choi; Jae Jung Lee; Hye Sun Lee; Young H Sohn; Jong-Min Lee; Phil Hyu Lee
Journal:  Hum Brain Mapp       Date:  2017-09-12       Impact factor: 5.038

9.  Clinical Implications of Cardiac-MIBG SPECT in the Differentiation of Parkinsonian Syndromes.

Authors:  Dong Hoon Shin; Phil Hyu Lee; Oh Young Bang; In Soo Joo; Kyoon Huh
Journal:  J Clin Neurol       Date:  2006-03-20       Impact factor: 3.077

10.  Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism.

Authors:  Phil Hyu Lee; Seung Hyeon Yeo; Seok Woo Yong; Yun Joong Kim
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-06-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.